List of Excipients in Branded Drug NARDIL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	NARDIL	phenelzine sulfate	0071-0350	CROSCARMELLOSE SODIUM
Parke-Davis Div of Pfizer Inc	NARDIL	phenelzine sulfate	0071-0350	EDETATE DISODIUM
Parke-Davis Div of Pfizer Inc	NARDIL	phenelzine sulfate	0071-0350	ISOPROPYL ALCOHOL
Parke-Davis Div of Pfizer Inc	NARDIL	phenelzine sulfate	0071-0350	MAGNESIUM STEARATE
Parke-Davis Div of Pfizer Inc	NARDIL	phenelzine sulfate	0071-0350	MANNITOL

Nardil Excipient Strategy and Commercial Opportunities for Phenelzine Sulfate

Last updated: October 25, 2026

Nardil, the brand name for phenelzine sulfate, is an older irreversible monoamine oxidase inhibitor used for major depressive disorder. Its commercial opportunity is not based on conventional mass-market volume. It is concentrated in specialty psychiatry, treatment-resistant depression, supply continuity, patient-friendly oral dosage forms, and differentiated generic or reformulated products.

The core excipient strategy should preserve dose accuracy, chemical stability, rapid and predictable release, low pill burden, and broad tolerability. The strongest commercial concepts are an improved immediate-release tablet, an orally disintegrating tablet, a lower-swallowing-burden presentation, and a reliable generic supply platform. Modified-release products have technical and clinical value but carry greater regulatory and development risk.

What is Nardil and how is phenelzine sulfate used?

Nardil contains phenelzine sulfate, an irreversible and nonselective monoamine oxidase inhibitor. The labeled dose is generally initiated at 15 mg three times daily and may be increased during treatment, followed by maintenance and tapering according to clinical response and tolerability (Pfizer, 2023).

Attribute	Nardil
Active ingredient	Phenelzine sulfate
Common strength	15 mg tablet
Therapeutic class	Monoamine oxidase inhibitor
Primary indication	Major depressive disorder
Dosage form	Immediate-release oral tablet
Regulatory status	Approved prescription drug
Generic pathway	Abbreviated New Drug Application, subject to FDA requirements
Biosimilar exposure	None
Principal safety constraints	Hypertensive reactions, serotonin syndrome, orthostatic hypotension, hepatic effects, and extensive drug and food interactions

Phenelzine is generally reserved for patients who have not responded adequately to other antidepressants or who cannot tolerate alternative therapies. The narrow patient population limits volume but supports specialty pricing and supply-based differentiation.

What excipients are used in Nardil tablets?

Public product labeling identifies inactive ingredients used in Nardil or phenelzine sulfate tablet presentations. Exact compositions can vary by manufacturer and manufacturing site. The established formulation platform uses conventional tablet excipients such as fillers, binders, disintegrants, lubricants, and coating materials.

Potential excipient categories include:

Excipient function	Commercial purpose	Key considerations for phenelzine
Diluent	Provides tablet mass and content uniformity	Low-dose active loading makes blend uniformity important
Binder	Supports tablet hardness	Excessive binding can delay disintegration
Disintegrant	Promotes breakup after swallowing	Useful for rapid, reproducible release
Lubricant	Supports compression and ejection	Excess levels can reduce dissolution or tablet strength
Glidant	Improves powder flow	Important for low-dose blend uniformity
Film coating	Protects tablet and improves swallowability	Must not materially delay immediate release
Colorant or opacifier	Supports product identification	Regulatory and patient-acceptance considerations
Moisture-control excipient or packaging system	Limits degradation risk	Relevant to long-term stability and supply-chain robustness

The commercial objective is not to add excipients for their own sake. Each excipient should support a measurable performance attribute: dissolution, content uniformity, tablet robustness, stability, swallowability, or manufacturing yield.

What excipient risks are important for phenelzine sulfate?

The main formulation risks are dose uniformity, chemical stability, dissolution consistency, and interaction with packaging or manufacturing equipment.

Phenelzine sulfate is administered at a relatively low dose compared with the total tablet mass. A formulation therefore needs effective powder blending and segregation control. A high-risk manufacturing process could produce tablet-to-tablet variability even when the nominal formulation is simple.

Potential development risks include:

1. Inadequate blend uniformity caused by differences in particle size, density, or electrostatic behavior.
2. Excessive lubricant use that slows dissolution.
3. Moisture uptake that affects stability, tablet hardness, or assay.
4. Incompatibility between phenelzine sulfate and reactive excipient impurities.
5. Coating systems that produce delayed or variable release.
6. Packaging interactions involving moisture, oxygen, or light.
7. Patient intolerance to dyes, lactose, gluten-containing excipients, or other avoidable formulation components.

An excipient screen should evaluate solid-state compatibility, assay, related substances, dissolution, water activity, accelerated stability, and container-closure performance. The drug’s long commercial history creates a reference-product comparison requirement. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway, not simply reproduce a visually similar tablet (U.S. Food and Drug Administration [FDA], 2024a).

What formulation patents protect Nardil?

Nardil is an older small-molecule product. The original product and formulation patents are expected to be expired or otherwise commercially irrelevant in the United States. The principal opportunity is therefore not an original Nardil patent estate but a new patent estate covering a differentiated phenelzine product.

Potentially protectable subject matter includes:

Patent strategy	Possible claim scope	Commercial value
Orally disintegrating tablet	Phenelzine particle size, excipient ratios, disintegration time, mechanical strength	Reduces swallowing burden
Taste-masked formulation	Coating, complexation, ion exchange, or multiparticulate system	Improves adherence if taste is limiting
Modified release	Matrix, reservoir, or multiparticulate release profile	Could reduce dosing frequency
Stability formulation	Specific excipient combination and moisture-control system	Supports extended shelf life
Low-dose tablet platform	Content uniformity and compression process	Supports flexible titration
Packaging patent	Moisture-barrier container and desiccant configuration	Protects stability architecture
Combination product	Phenelzine with a separately regulated adjunct	Higher clinical and regulatory complexity

A new formulation patent must show more than a routine substitution of one conventional excipient for another. Stronger claims would link the excipient system to an unexpected technical result, such as improved stability, dissolution, dose uniformity, or manufacturability.

When does Nardil lose exclusivity?

Nardil’s original small-molecule exclusivity period has long expired. No new chemical entity exclusivity remains relevant to the product. The commercial market is therefore governed primarily by generic competition, manufacturing economics, supply reliability, prescribing demand, and any later patents covering a reformulated product.

The practical exclusivity position is:

Exclusivity category	Nardil position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable based on the approved indication
Pediatric exclusivity	No current commercial significance
Original product patents	Expired or commercially exhausted
Formulation patents	Relevant only if separately developed and granted
Method-of-use patents	Limited value for a legacy broad indication unless tied to a new protected use
Regulatory exclusivity for a new product	Potentially available only through a qualifying reformulation or new indication

What is the Orange Book status of Nardil?

The FDA Orange Book identifies approved drug products and patent or exclusivity information relevant to generic substitution. A legacy Nardil listing should be checked against the current electronic Orange Book and the specific marketing status of the listed product before making an acquisition, launch, or litigation decision (FDA, 2024b).

For a new phenelzine product, Orange Book listing would depend on the product’s approval, active marketing status, and qualifying patents. A formulation patent could be listed if it meets FDA requirements. Method-of-use listings would depend on the approved labeling and the scope of the patent claims.

Because the original product is old, Orange Book value is more likely to arise from a newly approved differentiated product than from legacy Nardil intellectual property.

Are there Paragraph IV challenges to Nardil?

Any current Paragraph IV activity would relate to specific ANDAs, listed patents, or newly approved phenelzine products rather than to the original discovery position for phenelzine. Paragraph IV litigation risk is therefore transaction-specific.

A generic applicant could use a Paragraph IV certification against a listed formulation or method-of-use patent if an active patent were listed for the reference product. A legacy product with no relevant unexpired listed patents would present little conventional Paragraph IV exposure. The more significant risk would arise if a reformulated phenelzine product obtained listed patents covering an orally disintegrating, extended-release, or stability-enhanced formulation.

What are the best commercial excipient opportunities for Nardil?

Orally disintegrating phenelzine tablet

An orally disintegrating tablet could address patients with dysphagia, psychiatric comorbidity, difficulty swallowing, or poor adherence. The formulation would need rapid disintegration without unacceptable taste, friability, or moisture sensitivity.

Relevant excipients could include a highly soluble diluent, superdisintegrant, compressible filler, flavor system, and taste-masking component. The product would require careful control of phenelzine exposure during manufacture and storage.

Commercial value would depend on proving a meaningful patient benefit. A smaller, easier-to-administer tablet is more defensible than a simple excipient change with no clinical or adherence evidence.

Low-dose and titration-strength platform

Phenelzine treatment involves dose adjustment. A product family containing 7.5 mg, 15 mg, and 30 mg strengths could improve titration and reduce tablet splitting. The main technical challenge would be maintaining content uniformity at low drug loading.

A common excipient platform across strengths could reduce manufacturing complexity. A scored tablet, mini-tablet, or capsule-in-tablet design could provide additional dosing flexibility.

Improved stability product

A moisture-protective formulation could reduce degradation and improve shelf life. The opportunity may involve a low-moisture process, protective film coating, high-barrier blister, desiccant-equipped bottle, or a combination of these measures.

This strategy has commercial value when supply interruptions or short dating create pharmacy and wholesaler friction. Packaging patents may be more practical than broad composition claims if the technical benefit is primarily container-closure performance.

Taste-masked or multiparticulate formulation

Multiparticulates could support taste masking, flexible dosing, and modified release. The technology is more complex than a conventional tablet and may trigger greater bioequivalence and clinical scrutiny.

A multiparticulate product could be useful for patients unable to swallow tablets, but it would need to maintain the approved immediate-release exposure profile unless a new clinical development program supports a different pharmacokinetic design.

How does Nardil compare with competing antidepressants?

Phenelzine competes with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, tricyclic antidepressants, and newer therapies for treatment-resistant depression.

Product class	Patent position	Dosing convenience	Excipient opportunity	Commercial assessment
Phenelzine	Legacy product, largely off-patent	Moderate	High for adherence and supply reliability	Niche, specialty market
SSRIs	Mature generic markets	High	Limited differentiation	Large volume, intense price competition
SNRIs	Mixed legacy and newer estates	High	Moderate	Broad prescribing base
Tricyclics	Mature generic markets	Moderate	Moderate	Low-cost competition
Newer branded antidepressants	Active product patents may exist	Variable	High	Higher price, larger launch costs

Phenelzine’s commercial differentiation comes from its role in treatment-resistant disease, not from broad first-line prescribing. A formulation that reduces interaction with daily routines or improves reliable administration could capture value despite a small patient population.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are low-dose content uniformity, stability control, validated dissolution, and consistent supply of qualified raw materials. A manufacturer also needs robust change-control procedures because even minor excipient or process changes can affect dissolution and bioequivalence.

Potential barriers include:

• Qualification of phenelzine sulfate API suppliers.
• Control of particle-size distribution and polymorphic behavior.
• Segregation prevention during blending and transfer.
• Moisture and oxygen control.
• Reproducible compression at multiple strengths.
• Validated impurity methods.
• Stability data supporting the proposed shelf life.
• FDA requirements for ANDA formulation, manufacturing, and bioequivalence data.

A new formulation may obtain U.S. patents, but enforcement value depends on claim breadth, detectable infringement, and the size of the phenelzine market. Narrow excipient-ratio claims may be difficult to enforce unless the accused product’s formulation can be established through discovery or testing.

Which companies are positioned to challenge or commercialize Nardil?

Potential participants include generic manufacturers with psychiatric-product portfolios, contract development and manufacturing organizations, specialty pharmaceutical companies, and suppliers of orally disintegrating or multiparticulate technologies.

The most credible commercial models are:

1. A conventional ANDA launch focused on reliable supply and competitive cost.
2. A specialty-generic product with multiple strengths and improved packaging.
3. A 505(b)(2) reformulation using an orally disintegrating or alternative delivery system.
4. A licensing arrangement involving a formulation platform, specialty manufacturer, or psychiatric commercial partner.

No biosimilar pathway applies because phenelzine is a synthetic small molecule rather than a biologic. The relevant regulatory routes are an ANDA for a pharmaceutically equivalent product or, depending on the formulation and clinical claims, a 505(b)(2) application (FDA, 2024a).

What generic launch risks exist for Nardil?

Generic launch risk is moderate from a technical perspective and high from a market-size perspective. The product is not difficult because of a complex biologic structure, but small errors in blend uniformity, stability, or dissolution can create regulatory problems.

Commercial risks include:

• Limited eligible patient volume.
• Low reimbursement and pharmacy substitution pressure.
• Possible API supply constraints.
• Physician reluctance to change a stable patient’s product.
• Safety-monitoring burdens associated with MAOI therapy.
• Inventory volatility caused by a small number of manufacturers.
• Weak return on investment for a full reformulation program.

The strongest launch scenario is a supply-secure product with differentiated strengths, documented stability, and targeted distribution through psychiatric and specialty-pharmacy channels.

What licensing opportunities exist for Nardil formulations?

Licensing value is most likely in technology rather than in legacy Nardil rights. A formulation owner could license:

• Orally disintegrating tablet technology.
• Taste masking.
• Low-dose content-uniformity processes.
• Moisture-barrier packaging.
• Multiparticulate delivery.
• Specialty-generic commercialization rights.
• Regional manufacturing and distribution rights.

Geographic expansion should prioritize the United States, Canada, Europe, Japan, and markets with established use of MAOIs. Patent value will vary by jurisdiction, and national approval, supply, and reimbursement conditions may matter more than patent duration for an old active ingredient.

How strong is the Nardil patent estate?

The legacy Nardil patent estate is weak as a source of current exclusivity because phenelzine sulfate is an old active ingredient and the original product position is mature. A new formulation estate could be moderate if it combines composition, process, packaging, and use claims supported by comparative data.

Estate component	Expected strength
Original active-ingredient claims	Very weak or expired
Original tablet formulation claims	Weak or expired
New excipient composition	Moderate if technically non-obvious
Orally disintegrating formulation	Moderate to strong with unexpected performance
Modified-release formulation	Moderate, with high development risk
Packaging and stability claims	Moderate and commercially practical
Broad method-of-use claims	Generally limited for a legacy indication
Manufacturing process claims	Moderate if process-specific and difficult to design around

Key Takeaways

• Nardil contains phenelzine sulfate and is an established, off-patent MAOI product.
• The commercial market is specialized and driven by treatment-resistant depression, supply reliability, and patient adherence.
• The most practical excipient opportunities are orally disintegrating tablets, titration-friendly strengths, taste masking, and stability-enhanced packaging.
• A conventional generic is more commercially realistic than a high-cost extended-release program.
• New patent value would come from a differentiated formulation, process, or packaging system rather than from the legacy Nardil product.
• No biosimilar pathway applies.
• Paragraph IV exposure depends on active patents listed for a specific reference or reformulated product.
• The strongest launch strategy combines reliable API sourcing, multiple strengths, robust stability, and specialty distribution.

FAQs About Nardil Excipient Strategy and Commercialization

Can lactose-free phenelzine tablets be commercially differentiated?

Yes. A lactose-free formulation could appeal to patients with intolerance or excipient sensitivities, but the commercial benefit would need to exceed the cost of formulation development and labeling differentiation.

Is an orally disintegrating Nardil product eligible for a 505(b)(2) application?

Potentially. A materially different dosage form, pharmacokinetic profile, or administration method may support a 505(b)(2) pathway, subject to FDA requirements for bridging and clinical or bioavailability data.

Could a phenelzine transdermal product create a new patent estate?

Yes, but transdermal delivery would require substantial formulation, pharmacokinetic, safety, and clinical development. It would be a new product-development program rather than a simple generic strategy.

Does Nardil require a special excipient to prevent tyramine reactions?

No excipient eliminates the pharmacologic interaction risk associated with irreversible MAO inhibition. Excipient selection should focus on stability, tolerability, dose uniformity, and release performance.

Is phenelzine sulfate suitable for a liquid oral formulation?

A liquid could support patients who cannot swallow tablets, but solubility, chemical stability, taste, dosing accuracy, preservative compatibility, and packaging would require substantial development work.

References

1. Pfizer Inc. (2023). Nardil (phenelzine sulfate) tablets: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024a). ANDA submissions: Content and format. https://www.fda.gov/drugs/generic-drugs

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. National Library of Medicine. (2024). Nardil and phenelzine sulfate drug labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/